Aurobindo Pharma arm gets USFDA nod for generic blood cancer drug

Aurobindo Pharma's subsidiary, Eugia Pharma Specialities Ltd, has secured USFDA approval to produce and sell generic Dasatinib tablets, used for treating specific bone marrow and blood cancers. The approved tablets, available in multiple strengths, are therapeutically equivalent to Bristol-Myers Squibb's Sprycel. Launch is anticipated in Q1FY26, targeting a market with an estimated size of USD 1.8 billion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LySzHYd
via IFTTT